Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer
Article 2001 en
Authors
CP
Christos Papadimitriou
CK
Charalambos Kouroussis
LM
Lia A. Moulopoulos
Abstract
1 min read
The combination of ifosfamide, paclitaxel, and cisplatin is a well-tolerated outpatient regimen with significant activity in the treatment of newly diagnosed FIGO Stage III or IV epithelial ovarian carcinoma. Further evaluation is justified to clearly define the role of ifosfamide as an additional agent to the current platinum and paclitaxel regimens.
Gerasimos Aravantinos, George Fountzilas, Haralabos P. Kalofonos, D. Skarlos, P. Kosmidis, Irene Grimani, Nicholas Pavlidis, D. Bafaloukos, Dimitrios Pectasides, Meletios A Dimopoulos
Zacharias Kyriakakis, Meletios A Dimopoulos, A. Kostakopoulos, Aristidis Karayiannis, F. Sofras, Anastasios Zervas, Aristidis Giannopoulos, C Dimopoulos
Philip O'Brien, Michael J. Davies, James Scurry, A N Smith, Caroline Barton, Michelle J. Henderson, Darren N. Saunders, Brian Gloss, Kate Patterson, Jennifer L. Clancy, Viola Heinzelmann‐Schwarz, Richard A Scolyer, Y Zeng, Elizabeth D. Williams, L Scurr, Anna DeFazio, David I. Quinn, C. K. W. Watts, Neville F. Hacker, Susan M. Henshall, R. L. Sutherland
Discussion(0)
No comments yet. Be the first to comment.